OctoPlus Signs Service Contract with Galapagos
News Feb 16, 2009
OctoPlus N.V. has announced that it has signed a pharmaceutical development contract with a new client, Galapagos N.V. The undisclosed contract value significantly contributes to OctoPlus' annual revenues.
Under the contract terms, OctoPlus will manufacture clinical trial material for Galapagos' Phase II study of Nanocort®, a liposome formulation of prednisolone. OctoPlus has progressed the scale-up of the production process of this complex liposomal product.
OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition to its expertise in formulation and manufacturing, OctoPlus offers its clients drug delivery technologies for the development of controlled release versions of existing or new drugs.
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018